Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16047247 | 0.89 | KMT2A (0.52) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL18257681 | 0.88 | KMT2A (0.45) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL20565315 | 0.86 | KMT2A (0.44) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL31131464 | 0.84 | KMT2A (0.49) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL7909243 | 0.84 | KMT2A (0.49) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL10952894 | 0.83 | GSK3B (0.50) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL31315054 | 0.82 | KMT2A (0.50) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL6549496 | 0.81 | IDO1 (0.53) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL6057430 | 0.81 | ALDH1A1 (0.48) | KMT2AGSK3BPTPN1GPR139CES1 | |
| SCHEMBL22616327 | 0.81 | KMT2A (0.46) | KMT2AGSK3BPTPN1GPR139CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118804917-A | STAT modulators and uses thereof | 瑞克鲁迪克斯制药股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3943500-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | Agilent Technologies, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| EP-3137478-B1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES INC (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2019-06-27 | — | — | US | disclosed |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-6399782-B1 | ANTIDIABETIC AGENTS | METABASIS THERAPEUTICS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2002008235-A1 | MEDICAMENT FOR ORAL APPLICATION, CONTAINING AMINOPROPYL PHOSPHONIC ACID ESTERS AS AN ACTIVE INGREDIENT | JOMAA PHARMAKA GMBH (DE) | 2002-01-31 | — | — | WO | disclosed |
| EP-1100777-A1 | SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| EP-1100778-A1 | OXIDISED SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.p.A. (IT) | 2001-05-23 | — | — | EP | disclosed |
| US-6110903-A | INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE AT THE AMP SITE; ADMINISTERING TO TREAT DIABETES AND INHIBIT GLUCONEOGENESIS; 5-FLUORO-7-BROMO-1-ISOBUTYL-2-(2-PHOSPHONO-5-FURANYL) BENZIMIDAZOLE, FOR EXAMPLE | SANKYO COMPANY LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006542-A1 | OXIDISED SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006541-A1 | SULFURATED DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-02-10 | — | — | WO | disclosed |
| EP-0970095-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998039343-A9 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | — | 1999-01-21 | — | — | WO | disclosed |
| WO-1998039343-A1 | NOVEL BENZIMIDAZOLE INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194242-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | KMT2A 3723/4885GSK3B 4034/4885PTPN1 1526/4885 |
| US-10196418-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | KMT2A 3723/4885GSK3B 4034/4885PTPN1 1526/4885 |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | KMT2A 3723/4885GSK3B 4034/4885PTPN1 1526/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | KMT2A 3723/4885GSK3B 4034/4885PTPN1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.